News
News




T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the …

Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June 28 and received approval on August 20. The anticipated initiation of the Phase I trial remains by end of 2021. T-1301 Phase I trial is a multi-centered study in Taiwan. The oral solid dosage form …

Announces the Initiation of Phase I Clinical Trial of T-1201, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in …

Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the US FDA to enter clinical development
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1301 is a small molecular oral anti-cancer drug licensed from National Health Research Institutes in 2019. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …

T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the …

Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the Taiwan FDA to conduct Phase I clinical trial
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June 28 and received approval on August 20. The anticipated initiation of the Phase I trial remains by end of 2021. T-1301 Phase I trial is a multi-centered study in Taiwan. The oral solid dosage form …

Announces the Initiation of Phase I Clinical Trial of T-1201, A Novel Small-molecule Drug Conjugate (SMDC), in Taiwan
T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201 is a small molecular drug conjugate (SMDC), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1201, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in …

Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the US FDA to enter clinical development
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1301 is a small molecular oral anti-cancer drug licensed from National Health Research Institutes in 2019. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug …
Sorry, we couldn't find any posts. Please try a different search.




